Affimed

Affimed ROA

Delisted

The Return on Assets (ROA) of Affimed (AFMD) as of Nov 20, 2026 is -109.04 %. In the previous year, Return on Assets (ROA) was -42.89 % — a change of 154.21% (lower).

ROA

-109.04 %

YoY

154.21%

Last updated:

In 2023, Affimed's return on assets (ROA) was -109.04 %, a 154.21% increase from the -42.89 % ROA in the previous year.

The Affimed ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2016
-66.10 EUR
Jan 1, 2017
-70.03 EUR
Jan 1, 2018
-16.77 EUR
Jan 1, 2019
-28.80 EUR
Jan 1, 2020
-23.54 EUR
Jan 1, 2021
-25.55 EUR
Jan 1, 2022
-42.89 EUR
Jan 1, 2023
-109.04 EUR
The Affimed ROA history
YEARROAYoY
-109.04 %+154.21%
-42.89 %+67.87%
-25.55 %+8.54%
-23.54 %-18.28%
-28.80 %+71.81%
-16.77 %-76.06%
-70.03 %+5.95%
-66.10 %+159.06%
-25.51 %+4,028.60%
-0.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Affimed Stock analysis

What does Affimed do? Affimed NV develops targeted cancer immunotherapies focused on immuno-oncology, leveraging the immune system to combat tumor cells. The company's product pipeline includes AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma, AFM13 combined with adoptive NK cells or anti-PD-1, and AFM24 for advanced EGFR-expressing solid tumors. Affimed is conducting a registration-directed study for AFM13 and a Phase 1/2a study for AFM24, alongside preclinical candidates like AMF26 for multiple myeloma and AMF28/AMF32 for multiple tumor targets. The firm collaborates with Genentech to develop and commercialize certain product candidates for multiple cancers. Affimed generates revenue primarily through collaboration agreements, such as the partnership with Genentech, which covers development and commercialization of specific therapies. The company's primary customers are pharmaceutical and biotechnology firms seeking to expand their oncology portfolios, particularly those interested in immuno-oncology approaches. Affimed's target segments include patients with relapsed/refractory peripheral T-cell Lymphoma, advanced EGFR-expressing solid tumors, and multiple myeloma, as well as broader oncology markets for its preclinical candidates. The company's revenue streams are tied to milestone payments and potential royalties from partnered products, with Genentech being a key collaborator. Affimed's focus on immuno-oncology positions it to attract partnerships with major pharmaceutical players looking to enhance their cancer therapy offerings. Its clinical-stage products, such as AFM13 and AFM24, are in advanced development phases, making them attractive for strategic alliances that drive commercialization and revenue generation. Affimed is one of the most popular companies on Eulerpool.

ROA Details

Understanding Affimed's Return on Assets (ROA)

Affimed's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Affimed's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Affimed's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Affimed’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Affimed stock

Return on Assets (ROA) of Affimed is -109.04 % in 2023.

Return on Assets (ROA) of Affimed changed from -42.89 % to -109.04 %, representing a 154.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Affimed since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Affimed with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Affimed

All Key Metrics — Affimed